PLSE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
434.0K
+8.2%
401.0K
+51.9%
264.0K
+207.0%
86.0K
0
Cost of Revenue
273.0K
-26.2%
370.0K
+42.3%
260.0K
-6.8%
279.0K
0
Gross Profit
161.0K
+419.4%
31.0K
+675.0%
4.0K
+102.1%
-193000
0
Operating Expenses
25.4M
+32.6%
19.2M
+5.1%
18.3M
-9.5%
20.2M
-0.5%
20.3M
R&D
17.0M
+34.8%
12.6M
+15.2%
10.9M
-4.1%
11.4M
-5.7%
12.1M
SG&A
8.5M
+28.3%
6.6M
-10.1%
7.3M
-16.5%
8.8M
+7.3%
8.2M
Operating Income
-25272000
-32.0%
-19150000
-4.9%
-18253000
+10.4%
-20367000
-0.5%
-20275000
EBITDA
-25018000
-32.4%
-18895000
-5.0%
-17994000
+10.5%
-20111000
-0.5%
-20002000
Net Income
-24657000
-32.7%
-18581000
-6.6%
-17433000
+10.1%
-19385000
-1.1%
-19168000
EPS (Basic)
$-0.36
-33.3%
$-0.27
-3.8%
$-0.26
+10.3%
$-0.29
-3.6%
$-0.28
EPS (Diluted)
$-0.36
-33.3%
$-0.27
-3.8%
$-0.26
+10.3%
$-0.29
-3.6%
$-0.28
Shares (Diluted)
69.2M
+1.8%
68.0M
+0.3%
67.8M
+0.6%
67.4M
+0.2%
67.3M
Pulse Biosciences, Inc (DE) (PLSE) โ€” Financials